Genomics has gained a leading role within clinical medicine over the last decade, making deep inroads into oncology (cancer), cardiology, neurology, and other medical science fields. By offering new diagnostic, prognostic, and therapeutic options, has played an instrumental role in the study of different infectious and rare diseases. Different research studies have helped to explain that genomics can play a key role in “precision medicine” by developing individualized care for each patient in areas such as risk assessment and disease detection, disease control, treatment response, and more. In order to optimize a patient’s reaction to a treatment plan, pharmacogenomic tests are being created and used to help doctors assess therapeutic strategies that can classify specific genetic traits or combinations of traits.

Gene therapy and alternatives to gene-based therapy (including CAR T-cell therapies and genome editing based on CRISPR/Cas9) have revolutionized clinical medicine and specialty care for many previously untreatable chronic, rare or malignant diseases. 30-60 gene therapies are expected to be applied to clinical medicine by 2030, based on current trends in growth. Around 350,000 patients with lymphoma, leukemia, and other congenital or rare disorders are expected to be treated with these therapies.

While modern medicine is rapidly revolutionizing genomics, there have been some challenges to scaling up its use in healthcare. Costs, data complexity, the need for more skills, and the changing legal structure are some of the healthcare genomics challenges.

By combining awareness, enhancing education and training, informing public policy, helping to build and measure health systems, and more, public health genomics is poised to resolve the challenges of global population health. In various population subgroups, genomic technology can classify the influence of genomic variants and then provide personalized treatments that are more applicable to their risk level, resulting in more efficient and reliable strategies for disease prevention, screening, and surveillance.